Text Size

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

This study has been completed.
Sponsor:
Information provided by:
Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
ClinicalTrials.gov Identifier:
NCT00415597
First received: December 21, 2006
Last updated: December 7, 2009
Last verified: December 2009
History of Changes
  Purpose

Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.


Condition Intervention Phase
Pain
 Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Long-Term, Open-Label Safety Study of ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended-Release) Capsules in Subjects With Chronic Moderate to Severe Nonmalignant Pain

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.:

Primary Outcome Measures:
  • Subjects With Treatment Emergent Adverse Events [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Mean Percent Change From Baseline to 12 Weeks in Brief Pain Inventory Score (BPI) of Average Pain [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Mean Percent Change From Baseline to 52 Weeks in Brief Pain Inventory Score (BPI) of Average Pain [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

Enrollment: 467
Study Start Date: December 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ALO-01
Doses given once or twice daily
 Drug: ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
Other Name: Embeda

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject 18-70 years of age
  • Subject agrees to refrain from taking any opioid medications other than study medication during study period.
  • History of chronic moderate to severe pain caused by a nonmalignant condition for at least 3 months prior to baseline

Exclusion Criteria:

  • Subject has a documented history of allergic reaction or clinically significant intolerance to morphine or other opioids, such that treatment with morphine is contraindicated.
  • Subject is pregnant or breast-feeding.
  • Subject is receiving chemotherapy, or has an active malignancy of any type or has been diagnosed with cancer within the past three years (excluding squamous or basal cell carcinoma of the skin).
  • Subject has a documented history of drug abuse/dependence/misuse or narcotic analgesic abuse/dependence/misuse within five years prior to the Baseline Visit.
  • Subject has a Body Mass Index (BMI)>45kg/m2.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00415597

  Show 58 Study Locations
Sponsors and Collaborators
Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.
Investigators
Study Director: James B. Jones, MD, PharmD Alpharma Pharmaceuticals
  More Information

No publications provided by Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Kenneth Sommerville, M.D., FAAN, Vice President, Clinical Development, King Pharmaceuticals Research and Development, Inc.
ClinicalTrials.gov Identifier: NCT00415597     History of Changes
Other Study ID Numbers: ALO-KNT-302
Study First Received: December 21, 2006
Results First Received: September 11, 2009
Last Updated: December 7, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by Alpharma Pharmaceuticals LLC, a subsidiary of Pfizer Inc.:
chronic pain
joint pain
back pain
diabetic peripheral neuropathy
 post herpetic neuralgia
ALO-01
Embeda
Chronic Non-Malignant Pain

Additional relevant MeSH terms:
Naltrexone
Morphine
Narcotic Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
 Central Nervous System Agents
Therapeutic Uses
Analgesics, Opioid
Analgesics
Central Nervous System Depressants
Narcotics

ClinicalTrials.gov processed this record on May 22, 2013